|
Abilify (aripiprazole) approved for marketing in Europe for the treatment of schizophrenia.
Publication: Asia Africa Intelligence Wire Publication Date: 07-JUN-04 |
|
|
|
How to access the full article: Free access to all articles is available courtesy of your local library. To access the full article click the "See the full article" button below. You will need your US library barcode or password.
|
|
|
COPYRIGHT 2004 Financial Times Ltd.
(From Chemical Business NewsBase - Press Release)
Bristol-Myers Squibb Co and Otsuka Pharmaceutical Co Ltd (Otsuka) announced that the European Commission has granted marketing authorisation for Abilify (aripiprazole), an antipsychotic medication, for the treatment of schizophrenia. Receiving marketing approval for Abilify in 25 nations of the European Union marks...
Read the full article for free courtesy of your local library.
|
|
|
|
 |
| More Articles from Asia Africa Intelligence Wire |
Mother runs down tot in tragedy.
June 13, 2004
|
Studies show GlaxoSmithKline's Requip (ropinirole HCl) significantly i...
June 07, 2004
|
TAIWAN NEWSPAPER HIGHLIGHTS - JUNE 14, 2004.
June 14, 2004
|
BRIEFING - ASIA AVIATION - JUNE 14, 2004.
June 14, 2004
|
BRIEFING - ASIA INFORMATION TECHNOLOGY - JUNE 14, 2004.
June 14, 2004
|
|
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
